Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Iron Overload and Anemia of Chronic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HFE2/HJV drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HFE2/HJV ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View HFE2 Products |
| Gene Delivery | HFE2/HJV Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View HFE2 Products |
| Benchmark Ab | Anti-HFE2/HJV (Sequence of DISC-0974) Recombinant positive control. |
View HFE2 Products |
| Validator | HFE2/HJV siRNA Set For knockdown verification. |
View HFE2 Products |
| Related Target A | BMP6 Primary ligand for HFE2/HJV in the hepcidin activation pathway. |
View BMP6 Products |
| Related Target B | TMPRSS6 Matriptase-2 protease that cleaves HFE2/HJV to downregulate signaling. |
View TMPRSS6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| RGM Family Counter-Screening (RGMa, RGMb off-target) | Recombinant RGMa and RGMb homolog proteins available with >95% purity for selectivity ELISA/Biacore. |
| Native Glycosylation for BMP6 Interaction | HEK293 host expression ensures native post-translational glycosylation required for BMP-co-receptor binding. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) based on DISC-0974 sequence included. |
| False Positives | Validated siRNA sets included for target knockdown and specificity confirmation. |
Live HFE2/HJV R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the HFE2/HJV (Hemojuvelin) pathway is rapidly gaining momentum, transitioning from basic iron biology to target-driven clinical trials. HFE2/HJV acts as a crucial bone morphogenetic protein (BMP) co-receptor, modulating the BMP-SMAD signaling cascade to regulate hepcidin, the master regulator of systemic iron homeostasis.
The race for HFE2/HJV therapeutics is intensifying, with major players shifting focus from traditional erythropoiesis-stimulating agents (ESAs) to targeted monoclonal antibodies that modulate the iron axis. As first-generation therapies reach the clinic, the next wave of R&D is targeting chronic inflammatory anemia and myelofibrosis-associated anemia, where overcoming hepcidin-mediated iron restriction is paramount.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Disc Medicine (DISC-0974) | Myelofibrosis Anemia, Chronic Kidney Disease (CKD) Anemia | BMP6-HJV Blocking Assay (Need high-purity HEK293-expressed ECD-Fc) |
| Soluble HJV Decoy | Academic / Early-stage Biotech | Juvenile Hemochromatosis, Iron Overload | Ligand Binding Assays (Need sequence-verified BMP6 and BMP2 proteins) |
| siRNA / Gene Silencing | Preclinical consortia | Hereditary Hemochromatosis | In vitro knockdown validation (Need validated siRNA and stable reporter cell lines via Lentivirus) |